MedTrace Logo

The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23

NCT02097589 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2015-09-28

No results posted yet for this study

Summary

The purpose of this research study is to: Improve the effectiveness of vaccinations by identifying the effect of cholesterol medication, statins, on immune responses.

Conditions

  • Healthy Controls

Interventions

DRUG

Atorvastatin

10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days.

DRUG

Pneumovax 23

Pneumovax 23 injected once, intramuscularly at Day 7.

OTHER

Placebo (lactose pill)

10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days.

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Mark L Brantly, MD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02097589 on ClinicalTrials.gov